 Studies in cells and in mouse have shown that specifically targeting Amyloid beta-producing genes (e.g.BACE1 and APP) by RNAi can significantly reduced the amount of Aβ peptide which is correlated with the cause of Alzheimer's disease.In addition, this silencing-based approaches also provide promising results in treatment of Parkinson's disease and Polyglutamine disease.